Status:
TERMINATED
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Lead Sponsor:
Emory University
Collaborating Sponsors:
Celgene Corporation
Conditions:
B-Cell Lymphoma
Hodgkin's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. The purpose of this study is to find out what effects (good and bad) the drug thalidomide has...
Detailed Description
Patients who have relapsed or refractory large B-cell lymphoma are being asked to take part in this study. This research is being done because current treatment does not help everyone with this diseas...
Eligibility Criteria
Inclusion
- Patients with an expected survival period of 6 months or greater and who have been diagnosed with any stage of diffuse large B-cell lymphoma or Hodgkin's disease will be eligible to participate in this study. Final eligibility will be determined by the health professionals conducting this trial.
Exclusion
- Women who are pregnant, lactating or who refuse to have a pregnancy test will not be eligible for this study. Also, patients with an active infection, or a history of current or previous deep vein thrombosis and/or currently receiving anticoagulant therapy for deep vein thrombosis will be excluded from participation in this study. Final eligibility will be determined by the health professionals conducting this trial.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00209014
Start Date
July 1 2003
End Date
June 1 2006
Last Update
May 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322